Kelsey Moroz

Switching between daily recombinant human growth hormone preparations was not associated with worse growth or biochemical outcomes in children with growth hormone deficiency, according to a study. The retrospective single-center cohort analysis included 130 children with growth hormone deficiency, of whom 66 switched once between growth hormone products and 64 remained on the same therapy.

Long-term treatment with evinacumab produced sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other lipid measures in adolescent and adult Japanese patients with homozygous familial hypercholesterolemia (HoFH), according to results from a subgroup analysis of the Phase 3 ELIPSE HoFH open-label extension study.

Baxfendy (baxdrostat) has been approved by the US Food and Drug Administration as a first-in-class aldosterone synthase inhibitor for adults with hypertension who remain inadequately controlled despite treatment with other antihypertensive medications. Baxfendy is designed to lower blood pressure by selectively inhibiting aldosterone production.